{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T05:11:18Z","timestamp":1793682678459,"version":"4.5.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001698","name":"Israel Cancer Research Fund","doi-asserted-by":"publisher","award":["PROF-18-682"],"award-info":[{"award-number":["PROF-18-682"]}],"id":[{"id":"10.13039\/100001698","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"European Research Council","doi-asserted-by":"publisher","award":["835227"],"award-info":[{"award-number":["835227"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["1969\/18"],"award-info":[{"award-number":["1969\/18"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014972","name":"Egg Farmers of Canada","doi-asserted-by":"publisher","award":["862580"],"award-info":[{"award-number":["862580"]}],"id":[{"id":"10.13039\/100014972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jconrel.2025.113812","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T11:05:58Z","timestamp":1746183958000},"page":"113812","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Radiation-guided nanoparticles enhance the efficacy of PARP inhibitors in primary and metastatic BRCA1-deficient tumors via immunotherapy"],"prefix":"10.1016","volume":"383","author":[{"given":"Rami","family":"Khoury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Longobardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania T.","family":"Barnatan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Venkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9rica","family":"Garc\u00eda Alvarado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Yona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Green Buzhor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shir","family":"Shahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita C.","family":"Ac\u00farcio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita C.","family":"Guedes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena F.","family":"Florindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean J.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronit","family":"Satchi-Fainaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jconrel.2025.113812_bb0005","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/carcin\/bgq069","article-title":"BRCA1 and BRCA2: breast\/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair","volume":"31","author":"O'Donovan","year":"2010","journal-title":"Carcinogenesis"},{"issue":"13","key":"10.1016\/j.jconrel.2025.113812_bb0010","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2015.65.0747","article-title":"Frequency of germline mutations in 25 Cancer susceptibility genes in a sequential series of patients with breast Cancer","volume":"34","author":"Tung","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.jconrel.2025.113812_bb0015","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju091","article-title":"Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: a systematic review and meta-analysis","volume":"106","author":"Friebel","year":"2014","journal-title":"JNCI J. Natl. Cancer Inst."},{"issue":"11","key":"10.1016\/j.jconrel.2025.113812_bb0020","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/jnci\/djt095","article-title":"Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE","volume":"105","author":"Mavaddat","year":"2013","journal-title":"JNCI J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113812_bb0025","article-title":"BRCA-associated ovarian cancer: from molecular genetics to risk management","volume":"2014","author":"Girolimetti","year":"2014","journal-title":"Biomed. Res. Int."},{"issue":"6330","key":"10.1016\/j.jconrel.2025.113812_bb0030","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.jconrel.2025.113812_bb0035","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.jconrel.2025.113812_bb0040","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast Cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.jconrel.2025.113812_bb0045","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/annonc\/mdw133","article-title":"Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1\/2 mutation: a multistudy analysis of response rates and safety","volume":"27","author":"Matulonis","year":"2016","journal-title":"Ann. Oncol."},{"issue":"26","key":"10.1016\/j.jconrel.2025.113812_bb0050","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in patients with newly diagnosed advanced ovarian Cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113812_bb0055","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol."},{"issue":"32","key":"10.1016\/j.jconrel.2025.113812_bb0060","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1200\/JCO.18.02238","article-title":"Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16\/NOVA trial","volume":"37","author":"Campo","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113812_bb0065","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.annonc.2020.10.470","article-title":"A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance","volume":"32","author":"Tobalina","year":"2021","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113812_bb0070","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/j.ijrobp.2011.02.027","article-title":"Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases","volume":"82","author":"Sperduto","year":"2012","journal-title":"Intern. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113812_bb0075","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10555-020-09881-y","article-title":"Molecular and cellular mechanisms underlying brain metastasis of breast cancer","volume":"39","author":"Hosonaga","year":"2020","journal-title":"Cancer Metastasis Rev."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113812_bb0080","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.trecan.2019.12.004","article-title":"Therapeutic application of PARP inhibitors in neuro-oncology","volume":"6","author":"Ning","year":"2020","journal-title":"Trends Cancer"},{"issue":"7","key":"10.1016\/j.jconrel.2025.113812_bb0085","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","article-title":"Combination Cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy","volume":"171","author":"Palmer","year":"2017","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.jconrel.2025.113812_bb0090","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1200\/JCO.2011.37.6418","article-title":"Development of therapeutic combinations targeting major cancer signaling pathways","volume":"31","author":"Yap","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113812_bb0095","first-page":"66","article-title":"Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer","volume":"2","author":"Mehta","year":"2021","journal-title":"Nat. Can."},{"issue":"16","key":"10.1016\/j.jconrel.2025.113812_bb0100","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1158\/1078-0432.CCR-20-0056","article-title":"Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study","volume":"26","author":"Lampert","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.jconrel.2025.113812_bb0105","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","article-title":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study","volume":"21","author":"Domchek","year":"2020","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113812_bb0110","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1990","article-title":"Polyester nanoparticles delivering chemotherapeutics: learning from the past and looking to the future to enhance their clinical impact in tumor therapy","volume":"16","author":"Longobardi","year":"2024","journal-title":"WIREs Nanomed. Nanobiotechnol."},{"issue":"8","key":"10.1016\/j.jconrel.2025.113812_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23084153","article-title":"Crossing the blood-brain barrier: advances in nanoparticle technology for drug delivery in neuro-oncology","volume":"23","author":"Hersh","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113812_bb0120","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.drudis.2020.12.016","article-title":"Nanomedicine-driven molecular targeting, drug delivery, and therapeutic approaches to cancer chemoresistance","volume":"26","author":"Khot","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2025.113812_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122618","article-title":"Non-covalent strategies to functionalize polymeric nanoparticles with NGR peptides for targeting breast cancer","volume":"633","author":"Conte","year":"2023","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113812_bb0130","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41467-018-03705-y","article-title":"Progress and challenges towards targeted delivery of cancer therapeutics","volume":"9","author":"Rosenblum","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.113812_bb0135","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jconrel.2014.05.025","article-title":"Anticancer polymeric nanomedicine bearing synergistic drug combination is superior to a mixture of individually-conjugated drugs","volume":"187","author":"Markovsky","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113812_bb0140","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jconrel.2016.06.037","article-title":"In vivo comparative study of distinct polymeric architectures bearing a combination of paclitaxel and doxorubicin at a synergistic ratio","volume":"257","author":"Baabur-Cohen","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113812_bb0145","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jconrel.2019.03.015","article-title":"Threatening cancer with nanoparticle aided combination oncotherapy","volume":"301","author":"Rawal","year":"2019","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113812_bb0150","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-22186-0","article-title":"P-selectin axis plays a key role in microglia immunophenotype and glioblastoma progression","volume":"12","author":"Yeini","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.113812_bb0155","article-title":"CCL2 blockade combined with PD-1\/P-selectin immunomodulators impedes breast cancer brain metastasis","author":"Israeli Dangoor","year":"2024","journal-title":"Brain"},{"issue":"50","key":"10.1016\/j.jconrel.2025.113812_bb0160","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adr4762","article-title":"Two-in-one nanoparticle platform induces a strong therapeutic effect of targeted therapies in P-selectin\u2013expressing cancers","volume":"10","author":"Koshrovski-Michael","year":"2024","journal-title":"Sci. Adv."},{"issue":"345","key":"10.1016\/j.jconrel.2025.113812_bb0165","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf7374","article-title":"P-selectin is a nanotherapeutic delivery target in the tumor microenvironment","volume":"8","author":"Shamay","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113812_bb0170","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41563-023-01481-9","article-title":"P-selectin-targeted nanocarriers induce active crossing of the blood\u2013brain barrier via caveolin-1-dependent transcytosis","volume":"22","author":"Tylawsky","year":"2023","journal-title":"Nat. Mater."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113812_bb0175","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1038\/s41467-022-30568-1","article-title":"STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer","volume":"13","author":"Wang","year":"2022","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.jconrel.2025.113812_bb0180","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1016\/j.celrep.2018.11.054","article-title":"PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian Cancer","volume":"25","author":"Ding","year":"2018","journal-title":"Cell Rep."},{"issue":"14","key":"10.1016\/j.jconrel.2025.113812_bb0185","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP inhibitor upregulates PD-L1 expression and enhances Cancer-associated immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.jconrel.2025.113812_bb0190","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004695","article-title":"Therapeutic targeting of PD-1\/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment","volume":"10","author":"Acurcio","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113812_bb0195","doi-asserted-by":"crossref","first-page":"E22","DOI":"10.3390\/molecules21010022","article-title":"Detecting and quantifying biomolecular interactions of a dendritic polyglycerol sulfate nanoparticle using fluorescence lifetime measurements","volume":"21","author":"Boreham","year":"2015","journal-title":"Molecules"},{"issue":"8","key":"10.1016\/j.jconrel.2025.113812_bb0200","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1002\/anie.202006457","article-title":"Understanding the interaction of polyelectrolyte architectures with proteins and biosystems","volume":"60","author":"Achazi","year":"2021","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.jconrel.2025.113812_bb0205","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejpb.2015.03.018","article-title":"Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy","volume":"93","author":"P\u00e9rez-Herrero","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113812_bb0210","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jconrel.2011.12.021","article-title":"Administration, distribution, metabolism and elimination of polymer therapeutics","volume":"161","author":"Markovsky","year":"2012","journal-title":"J. Control. Release"},{"issue":"23","key":"10.1016\/j.jconrel.2025.113812_bb0215","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA J. Am. Med. Assoc."},{"issue":"5645","key":"10.1016\/j.jconrel.2025.113812_bb0220","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2025.113812_bb0225","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.phrs.2017.07.023","article-title":"MDR in cancer: addressing the underlying cellular alterations with the use of nanocarriers","volume":"126","author":"Singh","year":"2017","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113812_bb0230","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1517\/17425247.2014.868881","article-title":"Core-shell nanocarriers for cancer therapy. Part I: biologically oriented design rules","volume":"11","author":"d\u2019Angelo","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113812_bb0235","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113812_bb0240","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/s41467-022-27987-5","article-title":"Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities","volume":"13","author":"Cosgrove","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113812_bb0245","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.cell.2019.06.002","article-title":"Inadequate DNA damage repair promotes mammary transdifferentiation, leading to BRCA1 breast cancer","volume":"178","author":"Wang","year":"2019","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.jconrel.2025.113812_bb0250","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191360","article-title":"Matrix compliance permits NF-\u03baB activation to drive therapy resistance in breast cancer","volume":"218","author":"Drain","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2025.113812_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.04.001","article-title":"Meet me halfway: are in vitro 3D cancer models on the way to replace in vivo models for nanomedicine development?","volume":"175","author":"Pozzi","year":"2021","journal-title":"Adv. Drug Deliv. Rev."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925004328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925004328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:34:27Z","timestamp":1778502867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925004328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":51,"alternative-id":["S0168365925004328"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113812","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiation-guided nanoparticles enhance the efficacy of PARP inhibitors in primary and metastatic BRCA1-deficient tumors via immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113812","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113812"}}